Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis
International Journal of Molecular Sciences · 29.05.2026 · 27 (11) · 4933
DOI: 10.3390/ijms27114933 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.05.2026. Verfasst von Lucienne Costa-Frossard und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis, Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), …. Hauptthemen laut MEDLINE: Neurofilament Proteins, Multiple Sclerosis, Relapsing-Remitting, Glial Fibrillary Acidic Protein, Oxadiazoles. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Relapsing–remitting multiple sclerosis (RRMS) is characterized by neuroaxonal damage, astrogliosis and inflammation. These mechanisms may already be active from early disease stages, underscoring the need for sensitive biomarkers capable of capturing treatment-related biological effects beyond conventional clinical measures. In this multicenter, ambispective, observational real-world study, the longitudinal effects of ozanimod on serum biomarkers were evaluated, during the first year of treatment in patients with low-to-moderate activity RRMS. Serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP) and cytokines associated with immune activity (IFN-γ, IL-17, IL-6, IL-10, and IL-1β) were quantified at baseline, 6 months, and 12 months using an ultrasensitive single-molecule array (SIMOA). Ozanimod was associated with significant reductions in sNfLs and sGFAP at 12 months. Concomitantly, significant decreases in IFN-γ and IL-1β were observed. IL-17 levels remained unchanged in the overall cohort but decreased in patients with higher baseline IL-17 levels. These findings demonstrate coordinated modulation of biomarkers reflecting neuroaxonal damage, astroglial activation, and inflammatory activity under ozanimod treatment in early RRMS in real-world conditions. These results highlight the biological relevance of early intervention within a therapeutic window of opportunity and support the potential utility of serum biomarkers for monitoring biological treatment effects in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis, Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), IRYCIS, Universidad de Alcalá, 28034 Madrid, Spain.
- Neuroimmunology Group, Department of Medicine, Department of Neurology, University of Lleida, IRBLleida, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain.
- Department of Neurology, Complejo Hospitalario Universitario de Orense, 32005 Orense, Spain.
- Department of Neurology, Hospital Miguel Servet, 50009 Zaragoza, Spain.
- Neuroimmunology and Multiple Sclerosis Unit, Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, 17001 Girona, Spain.
- Neuroimmunology Unit, Department of Medicine, Department of Neurology, University Autonoma de Madrid IRBLleida, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.
ORCID-Profile: Lucienne Costa-Frossard, Daniel Apolinar García-Estévez, María Rosario Blasco-Quílez, José E Meca-Lallana, Cristina Ramo Tello, Carmen Muñoz-Fernández, José María Prieto González, Antonio Candeliere-Merlicco, Olga Carmona, Laura Borrega, Francisco Gascón-Giménez
Förderung
- Bristol Myers Squibb
Zitieren
APA
Costa-Frossard, L., Brieva, L., García-Estévez, D. A., Martín-Martínez, J. M., Álvarez-Bravo, G., Blasco-Quílez, M. R., Meca-Lallana, J. E., Calles-Hernández, M. C., Ramo Tello, C., Muñoz-Fernández, C., Barbero, D. E., López-Muñoz, P., Prieto González, J. M., Candeliere-Merlicco, A., Carmona, O., Riancho, J., Sola-Valls, N., Carcelén-Gadea, M., Borrega, L., …, & Villar, L. M. (2026). Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis. International Journal of Molecular Sciences, 27(11), 4933. https://doi.org/10.3390/ijms27114933
Vancouver
Costa-Frossard L, Brieva L, García-Estévez DA, Martín-Martínez JM, Álvarez-Bravo G, Blasco-Quílez MR, et al. Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis. International Journal of Molecular Sciences. 2026;27(11):4933. doi:10.3390/ijms27114933
BibTeX
@article{CostaFrossard2026,
author = {Costa-Frossard, Lucienne and Brieva, Luis and García-Estévez, Daniel Apolinar and Martín-Martínez, Jesús Manuel and Álvarez-Bravo, Gary and Blasco-Quílez, María Rosario and Meca-Lallana, José E and Calles-Hernández, María Carmen and Ramo Tello, Cristina and Muñoz-Fernández, Carmen and Barbero, David Enrique and López-Muñoz, Pablo and Prieto González, José María and Candeliere-Merlicco, Antonio and Carmona, Olga and Riancho, Javier and Sola-Valls, Nuria and Carcelén-Gadea, María and Borrega, Laura and Gascón-Giménez, Francisco and Vilanova, David and Pérez, Xavier and Villar, Luisa María},
title = {Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {11},
pages = {4933},
doi = {10.3390/ijms27114933}
}
EUVIMED